Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma
A Phase Ⅱ, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With recurrent or metastatic ampulla tumors.
Ampullary Carcinoma
DRUG: Surufatinib+Toripalimab+AG
Objective response rate (ORR), Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year
Progression free survival (PFS), Tumor assessment will be performed using radiography method every 6 weeks, until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Overall survival (OS）, Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization until death due to any cause, assessed up to 3 year|Disease control rate (DCR）, Tumor assessment will be performed using radiography method every 6 weeks until the occurrence of progressive disease (PD), using RECIST v 1.1, from randomization up to progressive disease or EOT due to any cause, assessed up to 2 year|Safety and tolerance evaluated by incidence, severity and outcomes of AEs, Safety and tolerance will be evaluated by incidence, severity and outcomes of AEs and categorized by severity in accordance with the NCI CTC AE Version 5.0, from first dose to 30 days post the last dose
A Phase Ⅱ, single-arm study to assess the safety, tolerability, and efficacy of Surufatinib Combination With Toripalimab in Patients With recurrent or metastatic ampulla tumors.